Holen Sie sich die Stockscreener-App
11.65
1.56%
-0.185
Schlusskurs vom Vortag:
$11.84
Offen:
$12.2
24-Stunden-Volumen:
785.51K
Relative Volume:
0.61
Marktkapitalisierung:
$748.21M
Einnahmen:
$161.10M
Nettoeinkommen (Verlust:
$-308.60M
KGV:
-2.4946
EPS:
-4.67
Netto-Cashflow:
$-259.90M
1W Leistung:
-13.58%
1M Leistung:
-5.21%
6M Leistung:
+64.32%
1J Leistung:
-34.07%
1-Tages-Spanne:
$11.56
$12.50
1-Wochen-Bereich:
$11.38
$14.00
52-Wochen-Spanne:
$5.90
$20.38
Arvinas Inc Stock (ARVN) Company Profile
Firmenname
Arvinas Inc
Sektor
Branche
Telefon
203-535-1456
Adresse
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
11.65 | 760.09M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-10-15 | Herabstufung | Goldman | Neutral → Sell |
| 2025-09-24 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-09-17 | Fortgesetzt | Barclays | Overweight |
| 2025-06-02 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Herabstufung | Truist | Buy → Hold |
| 2025-05-02 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-02 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-03-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2024-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-01 | Eingeleitet | Goldman | Buy |
| 2023-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-11-20 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-10-23 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-01-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Eingeleitet | Barclays | Overweight |
| 2022-06-21 | Eingeleitet | Jefferies | Hold |
| 2022-05-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2022-01-19 | Eingeleitet | Goldman | Buy |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-09 | Eingeleitet | BofA Securities | Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-21 | Eingeleitet | Truist | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-12-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Perform |
| 2019-12-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-25 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-25 | Eingeleitet | Wedbush | Outperform |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-08-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-22 | Eingeleitet | Citigroup | Buy |
| 2018-10-22 | Eingeleitet | Goldman | Neutral |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Arvinas Inc Aktie (ARVN) Neueste Nachrichten
Can Arvinas Inc. expand its profit margins2025 Earnings Impact & Free High Return Stock Watch Alerts - mfd.ru
Arvinas (NASDAQ:ARVN) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Why retail investors favor Arvinas Inc. stockJuly 2025 WrapUp & Target Return Focused Stock Picks - mfd.ru
Arvinas (NASDAQ:ARVN) Shares Down 10.9%Here's Why - MarketBeat
Geopolitics Watch: What dividend growth rate does Arvinas Inc offerJuly 2025 Recap & AI Powered Market Entry Strategies - baoquankhu1.vn
Arvinas announces appointment of Randy Teel, Ph.D., as president, chief executive officer, and director - marketscreener.com
ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff - Stocktwits
New Haven-based biotech Arvinas names new CEO - Hartford Business Journal
Arvinas appoints Randy Teel as new CEO - Traders Union
Arvinas (ARVN) Appoints New CEO as Leadership Changes Unfold - GuruFocus
Arvinas Announces Leadership Transition and New CEO Appointment - TipRanks
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director - GlobeNewswire
(ARVN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Arvinas (ARVN) to Release Quarterly Earnings on Tuesday - MarketBeat
Pfizer and Arvinas' breast cancer therapy to be reviewed by FDA - MSN
Arvinas, Inc. (ARVN) Stock Analysis: Unveiling Insights Into Its Biotech Potential - DirectorsTalk Interviews
Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Market Moves: How does Radius Recycling Inc perform in inflationary periodsEarnings Miss & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Y Intercept Hong Kong Ltd Buys 137,794 Shares of Arvinas, Inc. $ARVN - MarketBeat
There Is A Reason Arvinas, Inc.'s (NASDAQ:ARVN) Price Is Undemanding - 富途牛牛
Gains Recap: Can Arvinas Inc reach all time highs this yearWeekly Market Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Arvinas, Inc. (ARVN) Stock Analysis: Navigating The Biotech Frontier With Potential Upside - DirectorsTalk Interviews
Arvinas CEO John Houston to retire - MSN
New nanoparticle technology offers hope for hard-to-treat diseases - GlobeNewswire Inc.
Trading Systems Reacting to (ARVN) Volatility - Stock Traders Daily
Nordea Investment Management AB Grows Position in Arvinas, Inc. $ARVN - MarketBeat
Breakout Move: Can Arvinas Inc grow without external fundingJuly 2025 Spike Watch & Precise Buy Zone Identification - baoquankhu1.vn
Arvinas, Inc. $ARVN Stock Position Boosted by Campbell & CO Investment Adviser LLC - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Short Interest Down 27.9% in December - MarketBeat
Metastatic Prostate Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Merck, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis - Barchart.com
Short Squeeze: Will Arvinas Inc stock gain from government policies2025 Institutional Moves & Precise Swing Trade Alerts - Bộ Nội Vụ
TAC to the future: Where induced proximity is pointing in 2026 - BioCentury
Here's Why We're Not Too Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Situation - Yahoo Finance
Arvinas draws Wedbush downgrade after data for Pfizer-partnered cancer drug - MSN
Can Arvinas Inc. stock sustain institutional interestWeekly Earnings Recap & Real-Time Volume Surge Alerts - Улправда
Why Arvinas Inc. stock remains on buy lists2025 Winners & Losers & Weekly Top Performers Watchlists - Улправда
How Arvinas Inc. (ARVN) Affects Rotational Strategy Timing - Stock Traders Daily
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - sharewise.com
Arvinas, Inc. (ARVN) Stock Analysis: Examining the Biotech’s Potential with Recent Analyst Ratings - DirectorsTalk Interviews
Is Arvinas Inc. stock positioned well for digital economyPortfolio Return Report & Capital Efficiency Focused Ideas - ulpravda.ru
Movement Recap: Why Arvinas Inc. stock remains resilient2025 AllTime Highs & Expert Verified Movement Alerts - Улправда
Will Arvinas Inc. stock remain a Wall Street favoriteJuly 2025 Patterns & AI Enhanced Market Trend Forecasts - Улправда
Arvinas Plunges 45% After Pfizer-Partnered Drug Disappoints - MSN
Sentiment Watch: Is Arvinas Inc. stock positioned for long term growthTrade Analysis Report & Risk Managed Investment Strategies - Улправда
Citigroup upgrades Arvinas (ARVN) - MSN
Citigroup Upgrades Arvinas (ARVN) - Nasdaq
Arvinas (NASDAQ:ARVN) Shares Gap UpTime to Buy? - MarketBeat
ARVN Stock: Citigroup Upgrades Arvinas to 'Buy' with 50% Target - GuruFocus
Arvinas (NASDAQ:ARVN) Shares Down 2.6%Should You Sell? - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Aug Patterns: Will Arvinas Inc stock remain a Wall Street favorite2025 Top Gainers & Safe Investment Capital Preservation Plans - moha.gov.vn
Finanzdaten der Arvinas Inc-Aktie (ARVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):